chrX-49305448-A-T
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 0P and 2B. BP4_Moderate
The NM_001098413.4(GAGE10):c.126A>T(p.Glu42Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a benign outcome for this variant. 12/18 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.0 ( 0 hom., 0 hem., cov: 29)
Exomes 𝑓: 9.4e-7 ( 0 hom. 0 hem. )
Failed GnomAD Quality Control
Consequence
GAGE10
NM_001098413.4 missense
NM_001098413.4 missense
Scores
3
11
Clinical Significance
Conservation
PhyloP100: 0.407
Genes affected
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.13526666).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GAGE10 | NM_001098413.4 | c.126A>T | p.Glu42Asp | missense_variant | 3/5 | ENST00000407599.4 | NP_001091883.3 | |
GAGE10 | XM_024452325.1 | c.84A>T | p.Glu28Asp | missense_variant | 1/3 | XP_024308093.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GAGE10 | ENST00000407599.4 | c.126A>T | p.Glu42Asp | missense_variant | 3/5 | 5 | NM_001098413.4 | ENSP00000385415.3 |
Frequencies
GnomAD3 genomes AF: 0.00 AC: 0AN: 110365Hom.: 0 Cov.: 29 AF XY: 0.00 AC XY: 0AN XY: 32681 FAILED QC
GnomAD3 genomes
AF:
AC:
0
AN:
110365
Hom.:
Cov.:
29
AF XY:
AC XY:
0
AN XY:
32681
FAILED QC
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome Data not reliable, filtered out with message: AS_VQSR AF: 9.37e-7 AC: 1AN: 1067335Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 345029
GnomAD4 exome
Data not reliable, filtered out with message: AS_VQSR
AF:
AC:
1
AN:
1067335
Hom.:
Cov.:
31
AF XY:
AC XY:
0
AN XY:
345029
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 110365Hom.: 0 Cov.: 29 AF XY: 0.00 AC XY: 0AN XY: 32681
GnomAD4 genome
Data not reliable, filtered out with message: AC0
AF:
AC:
0
AN:
110365
Hom.:
Cov.:
29
AF XY:
AC XY:
0
AN XY:
32681
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 16, 2023 | The c.126A>T (p.E42D) alteration is located in exon 3 (coding exon 2) of the GAGE10 gene. This alteration results from a A to T substitution at nucleotide position 126, causing the glutamic acid (E) at amino acid position 42 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
FATHMM_MKL
Benign
N
M_CAP
Benign
T
MetaRNN
Benign
T
MetaSVM
Benign
T
PrimateAI
Benign
T
PROVEAN
Benign
N
REVEL
Benign
Sift
Uncertain
D
Sift4G
Uncertain
D
Vest4
MutPred
Loss of glycosylation at P40 (P = 0.1075);
MVP
MPC
ClinPred
T
GERP RS
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.